BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024 at 11.30 am PST
POMPANO BEACH, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization
of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV.,
from April 30 - May 2 2024.
BioStem’s Chief Executive Officer, Jason Matuszewski, will present on Wednesday, May 1, 2024 at 11.30 am PST, and will discuss the company’s expected milestones and growth strategy for 2024. Following the event, BioStem’s presentation will be available to view here: https://www.webcaster4.com/Webcast/Page/3026/50201.
The 2024 Planet MicroCap Showcase will combine company presentations with educational panels and 1:1 meetings. The event will bring together the best investors and thought leaders in MicroCap, and high quality MicroCap investing opportunities.
To request a meeting with Mr. Matuszewski, please contact PCG Advisory on 646-863-6893, or visit https://planetmicrocapshowcase.com/signup. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.
Lesen Sie auch
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative
therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain processing method. BioREtain has been developed by applying the latest research
in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed
and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes
(cGMP). Our portfolio of quality brands includes AmnioWrap2, VENDAJE, VENDAJE AC and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA-registered and
AATB-accredited site in Pompano Beach, Florida. For more information, visit biostemtechnologies.com and follow us on Twitter and LinkedIn.